Table 4.
Full multivariate analysis for overall survival
| Variable | RR | (95% CI) | p value |
|---|---|---|---|
| Age ≥ 50 years | 1.18 | (0.78, 1.78) | 0.434 |
| ECOG performance status | |||
| 2 – 3 versus 0 – 1 | 1.15 | (0.76, 1.76) | 0.507 |
| Hydroxyproline/creatinine ratio (centered) | 1.06 | (1.02, 1.10) | 0.001 |
| Bone-specific alkaline phosphatase (U/L) | 1.00 | (0.99, 1.01) | 0.471 |
| Estrogen-receptor status versus negative | |||
| Positive | 0.78 | (0.44, 1.40) | 0.406 |
| Unknown | 1.53 | (0.67, 3.50) | 0.314 |
| Progesterone-receptor status versus negative | |||
| Positive | 0.58 | (0.33, 1.00) | 0.050 |
| Unknown | 0.51 | (0.24, 1.07) | 0.074 |
| Sites of metastasis (yes versus no) | |||
| Bone as only metastatic site | 0.75 | (0.44, 1.29) | 0.301 |
| Lung | 1.49 | (0.733, 3.01) | 0.273 |
| Liver | 0.84 | (0.435, 1.61) | 0.593 |
| Time from diagnosis of bone metastases to study entry, years | 1.21 | (1.05, 1.38) | 0.008 |
| Time from cancer diagnosis to study entry, years | 0.83 | (0.72, 0.95) | 0.008 |
| Lesion characteristics and numbers | |||
| ≥ 3 osteolytic versus < 3 osteolytic | 1.34 | (0.92, 1.95) | 0.128 |
| 1 – 2 osteoblastic versus no osteoblastic | 1.19 | (0.74, 1.92) | 0.471 |
| ≥ 3 osteoblastic versus no osteoblastic | 0.79 | (0.36, 1.74) | 0.559 |
| 1 – 2 mixed versus no mixed | 0.64 | (0.36, 1.16) | 0.140 |
| ≥ 3 mixed versus no mixed | 0.63 | (0.35, 1.12) | 0.112 |
| Prior fracture (yes versus no) | 0.99 | (0.58, 1.67) | 0.964 |
| Pain scores (centered) | 1.03 | (0.96, 1.11) | 0.406 |
| Prior chemotherapy (yes versus no) | 1.54 | (0.46, 5.16) | 0.484 |
| ≥ 2 prior hormonal therapies (yes versus no) | 1.61 | (1.08, 2.40) | 0.020 |
| Prior radiotherapy (yes versus no) | 0.75 | (0.47, 1.20) | 0.230 |
Values in bold represent statistically significant correlations.
RR = Relative risk, CI = Confidence interval, ECOG = Eastern Cooperative Oncology Group, U = Units.